At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 120 enrolled
Drug / intervention
PRT-2761 0.5% +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Center, Randomized, Double-Masked, Vehicle and Active-Controlled, Dose-Ranging Phase 2 Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis Using the Conjunctival Allergen Challenge Model (Ora-CAC®)
In Brief
A Phase 2 clinical trial evaluating PRT-2761 0.5%, PRT-2761 1%, and 3 other interventions for Allergic Conjunctivitis. Completed, enrolled 120 participants across 1 site.
Detailed Summary
To evaluate the efficacy and safety of two concentrations of PRT-2761 as a topical ophthalmic solution for the treatment of the signs and symptoms of acute and chronic allergic conjunctivitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Conjunctivitis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartOct 2017
First PostedOct 2017
Primary CompletionFeb 2018
Study CompletionFeb 2018
TodayJul 2026
First PostedOct 25, 2017
Enrollment StartOct 13, 2017
Primary CompletionFeb 16, 2018
Study CompletionFeb 18, 2018
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 8.7 years ago
Interventions
PRT-2761 0.5%drug
Six drops in each eye over a 17 day period.
PRT-2761 1%drug
Six drops in each eye over a 17 day period.
Patanoldrug
Six drops in each eye over a 17 day period.
Pred-fortedrug
Four drops in each eye over a 3 day period.
PRT-2761 0%drug
Six drops in each eye over a 17 day period.